Notice of Extraordinary General Meeting in BioPhausia AB (publ), August 30, 2010

The shareholders of BioPhausia AB (publ) are hereby invited to the extraordinary
general meeting to be held on Monday, August 30, 2010 at 11.00 in the premises
of Advokatfirman Cederquist, Hovslagargatan 3 in Stockholm, Sweden. The meeting
premises will open for registration at 10.30.

Notification of attendance
Shareholders who wish to attend must:
both be registered on Tuesday, August 24, 2010 in the register of shareholders
kept by Euroclear Sweden AB,
and notify the company of their intention to participate in the EGM not later
than Tuesday, August 24, 2010 at 16.00 by post to BioPhausia AB,
Blasieholmsgatan 2, 111 48 STOCKHOLM, by fax on + 46 (0)8-407 64 39, or by
e-mail tobolagsstamma@biophausia.se. The shareholder's name, personal or
corporate identity number, address and telephone number and the registered
shareholding should be stated when registering.

Shareholders may exercise their rights at the EGM through an authorised
representative. Such authorisation must be in writing and cannot be older than
twelve months. Proxies, registration certificates and other documents of
authorisation should be received by the company at the above address by Tuesday,
August 24, 2010. Please note that original copies of the authorisation must be
sent or brought to the EGM. Proxy forms are available at BioPhausia's website,
www.biophausia.se. Shareholders who wish to exercise the right to bring a
maximum of two assistants to the EGM shall notify this and state the number of
assistants at the same time as the aforementioned notification to attend is
made.

Shareholders whose shares are registered in the name of a nominee must
temporarily re-register the shares in their own name with Euroclear Sweden AB in
order to have the right to participate in the meeting. Such re-registration,
so-called registration of voting rights, must be effected on Tuesday, August
24, 2010, and the nominee should thus be notified of this well in advance of
this date.

Proposed agenda
 1.          Opening of the Extraordinary General Meeting.
 2.          Election of chairman at the meeting.
 3.          Establishment and approval of the voting list.
 4.          Approval of the agenda.
 5.          Election of one or more persons appointed to verify the minutes.
 6.          Determination of whether the EGM has been duly convened.
 7.          Approval of the transfer of all shares in the subsidiary AllGen
Pharmaceuticals and Generics B.V. to a company owned by an employee
 8.          Closing of the Extraordinary General Meeting.

 Item 7        Approval of the transfer of all shares in the subsidiary AllGen
Pharmaceuticals and Generics B.V. to a company owned by an employee

The general meeting is proposed to approve BioPhausia AB's transfer of all
shares in AllGen Pharmaceuticals and Generics B.V (AllGen) to Ostwald Beheer B.V
pursuant to a transfer agreement dated 30 June 2010. Completion of the transfer
is conditional on the general meeting's approval of the transfer. Since Ostwald
Beheer B.V is owned by Mr Eric Jan Ostwald, who is the managing director of
AllGen, the transfer requires approval from the general meeting of BioPhausia AB
according to Chapter 16 of the Swedish Companies Act.

AllGen's business was acquired in 2007 from Ostwald Beheer B.V and has during
the time that BioPhausia AB has owned the company showed unsatisfactory
profitability. Due to changed market conditions in Holland, a further venture is
not considered to be in line with BioPhausia's current strategy. For the year
2009, the company had a turnover of SEK 10 million and a loss of SEK 1 million.
The purchase price amounts to a total of € 1.

Specific majority requirement
A valid decision by the EGM in accordance with the Board of Directors' proposal
according to item 7 requires that the decision of the EGM is supported by
shareholders who represent at least 90% of both the votes cast and the shares
represented at the EGM.

At the time of issuance of this notice there is a total of 342 555 069 shares in
BioPhausia, each representing one voting right, meaning that there is a total of
324 555 069 voting rights in BioPhausia.


                            Stockholm in August 2010
                     Board of Directors

                              BioPhausia AB (publ)

The information must be made public according to the securities market act and
the financial instruments trading act.


[HUG#1437605]